Prostaglandins in the fetal circulation following maternal ingestion of a prostaglandin synthetase inhibitor during mid-pregnancy.
To assess the possible effect upon the fetus of maternal ingestion of the prostaglandin synthetase inhibitor, mefenamic acid, taken during mid-pregnancy (15-22 weeks) to prevent spontaneous abortion, samples of fetal blood were collected at fetoscopy from 13 treated and 14 untreated control cases. Mefenamic acid levels in the fetus were 32-54% of those in the mothers in the treated group, while prostaglandins E2 (PGE2), 6-oxo-PGF1 alpha and PGFM were all slightly but not significantly lower in those patients given 500 mg mefenamic acid 40-180 min prior to sampling than in untreated controls. Results indicate that the prostaglandin synthetase inhibitor crosses the placenta at this early gestation and may possibly suppress fetal prostaglandin production.
MacKenzie
I Z
IZ
Graf
A K
AK
Mitchell
M D
MD
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000022:Abortion, Spontaneous / Q000188:drug therapy*; D016861:Cyclooxygenase Inhibitors; D015237:Dinoprost / Q000031:analogs & derivatives*; D015232:Dinoprostone; D005260:Female; D005312:Fetal Blood / Q000032:analysis*; D005332:Fetoscopy; D006801:Humans; D008431:Maternal-Fetal Exchange; D008528:Mefenamic Acid / Q000627:therapeutic use*; D011247:Pregnancy; D011458:Prostaglandins E / Q000097:blood*; D011460:Prostaglandins F / Q000097:blood*; D013997:Time Factors
D016861:Cyclooxygenase Inhibitors; D011458:Prostaglandins E; D011460:Prostaglandins F; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D008528:Mefenamic Acid; D015121:6-Ketoprostaglandin F1 alpha; D015237:Dinoprost; D015232:Dinoprostone